You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling

Article info

Article menu

This article has a correction. Please see:

Download PDFPDF

XML
Research Article
Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling

Authors

  • Dan Wang Biotherapy CenterThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China Cancer CenterThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China Henan Key Laboratory for Tumor Immunology and Biotherapy 450052 Zhengzhou Henan People’s Republic of China PubMed articlesGoogle scholar articles
  • Li Yang Biotherapy CenterThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China Cancer CenterThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China Henan Key Laboratory for Tumor Immunology and Biotherapy 450052 Zhengzhou Henan People’s Republic of China PubMed articlesGoogle scholar articles
  • Weina Yu Biotherapy CenterThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China Cancer CenterThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China Henan Key Laboratory for Tumor Immunology and Biotherapy 450052 Zhengzhou Henan People’s Republic of China PubMed articlesGoogle scholar articles
  • Qian Wu Biotherapy CenterThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China Cancer CenterThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China Henan Key Laboratory for Tumor Immunology and Biotherapy 450052 Zhengzhou Henan People’s Republic of China PubMed articlesGoogle scholar articles
  • Jingyao Lian Biotherapy CenterThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China Cancer CenterThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China Henan Key Laboratory for Tumor Immunology and Biotherapy 450052 Zhengzhou Henan People’s Republic of China PubMed articlesGoogle scholar articles
  • Feng Li Biotherapy CenterThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China Cancer CenterThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China Henan Key Laboratory for Tumor Immunology and Biotherapy 450052 Zhengzhou Henan People’s Republic of China PubMed articlesGoogle scholar articles
  • Shasha Liu Biotherapy CenterThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China Cancer CenterThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China Henan Key Laboratory for Tumor Immunology and Biotherapy 450052 Zhengzhou Henan People’s Republic of China PubMed articlesGoogle scholar articles
  • Aitian Li Biotherapy CenterThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China Cancer CenterThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China Henan Key Laboratory for Tumor Immunology and Biotherapy 450052 Zhengzhou Henan People’s Republic of China PubMed articlesGoogle scholar articles
  • Zhiang He Biotherapy CenterThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China Cancer CenterThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China Henan Key Laboratory for Tumor Immunology and Biotherapy 450052 Zhengzhou Henan People’s Republic of China PubMed articlesGoogle scholar articles
  • Jinbo Liu Department of Anorectal SurgeryThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China PubMed articlesGoogle scholar articles
  • Zhenqiang Sun Department of Anorectal SurgeryThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China PubMed articlesGoogle scholar articles
  • Weitang Yuan Department of Anorectal SurgeryThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China PubMed articlesGoogle scholar articles
  • Yi Zhang Biotherapy CenterThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China Cancer CenterThe First Affiliated Hospital of Zhengzhou University 450052 Zhengzhou Henan People’s Republic of China Henan Key Laboratory for Tumor Immunology and Biotherapy 450052 Zhengzhou Henan People’s Republic of China School of Life SciencesZhengzhou University 450001 Zhengzhou Henan People’s Republic of China PubMed articlesGoogle scholar articles

Citation

Wang D, Yang L, Yu W, et al
Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling
Journal for ImmunoTherapy of Cancer 2019;7:215. doi: 10.1186/s40425-019-0701-2
Online issue publication 
November 02, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.